葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GSK 葛兰素史克

盘后交易 12-11 17:54:08 EST

36.37

+0.43

+1.20%

盘后36.18

-0.20-0.54%

17:31 EST

最高36.42	最低36.14	成交量268.06万
今开36.23	昨收35.94	日振幅0.78%
总市值741.25亿	流通市值717.60亿	总股本20.38亿
成交额9,731万	换手率0.14%	流通股本19.73亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GSK","market":"US","secType":"STK","nameCN":"葛兰素史克","latestPrice":36.37,"timestamp":1702328400000,"preClose":35.94,"halted":0,"volume":2680625,"hourTrading":{"tag":"盘后","latestPrice":36.175,"preClose":36.37,"latestTime":"17:31 EST","volume":11214,"amount":407839.99233599997,"timestamp":1702333874383},"delay":0,"floatShares":1973040981,"shares":2038072618,"eps":3.611188,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.43,"latestTime":"12-11 17:54:08 EST","open":36.23,"high":36.42,"low":36.14,"amount":97305816.296875,"amplitude":0.007791,"askPrice":36.42,"askSize":1,"bidPrice":36.2,"bidSize":1,"shortable":3,"etf":0,"ttmEps":3.611188,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1702342800000},"adr":1,"listingDate":977893200000,"adjPreClose":35.94,"adrRate":2,"dividendRate":0.038479,"preHourTrading":{"tag":"盘前","latestPrice":36.22,"preClose":35.94,"latestTime":"09:29 EST","volume":10652,"amount":384710.24173999997,"timestamp":1702304999999},"postHourTrading":{"tag":"盘后","latestPrice":36.175,"preClose":36.37,"latestTime":"17:31 EST","volume":11214,"amount":407839.99233599997,"timestamp":1702333874383},"volumeRatio":1.134704},"requestUrl":"/m/hq/s/GSK","defaultTab":"news","newsList":[{"id":"2390317336","title":"葛兰素史克(GSK.US)子宫内膜癌新药Jemperli获欧盟批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2390317336","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2390317336?lang=zh_cn&edition=full","pubTime":"2023-12-11 16:26","pubTimestamp":1702283172,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克表示，其用于治疗一种子宫内膜癌的新药Jemperli在欧盟获得批准。葛兰素史克周一在一份声明中表示，这种免疫肿瘤疗法已被批准与化疗联合用于治疗一部分基因序列错误积累的成年患者。欧盟还将对Jemperli单独或化疗后的有条件批准转变为完全批准。哥本哈根大学医院首席肿瘤学家、葛兰素史克关键临床试验负责人Mansoor Raza Mirza表示，这一决定可能会“为欧盟某些晚期或复发子宫内膜癌患者制定新的治疗标准”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1036214.html","is_publish_highlight":false},{"id":"2388425163","title":"更新 1-葛兰素史克首席执行官称 RSV 疫苗第一年收入将突破 10 亿英镑","url":"https://stock-news.laohu8.com/highlight/detail?id=2388425163","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2388425163?lang=zh_cn&edition=full","pubTime":"2023-11-30 23:47","pubTimestamp":1701359238,"startTime":"0","endTime":"0","summary":"    路透伦敦11月30日 - 葛兰素史克  首席执行官艾玛-沃姆斯利周四表示，这家英国制药商生产的呼吸道合胞病毒 疫苗上市第一年的销售收入有望超过10亿英镑。葛兰素史克此前曾表示，随着该疫苗在美国的强势上市， ，2023 年全年的销售额可能在 9 亿英镑到 10 亿英镑之间。葛兰素史克公司正寄希望于将 Arexvy 打造成下一个畅销药，因为到本十年末，该公司将面临专利到期和现有畅销药收入下降的双重压力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false},{"id":"2386166643","title":"四环生物4连板，抗流感概念鱼龙混杂，合胞病毒引关注丨钛媒体焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2386166643","media":"钛媒体APP","top":-1,"share":"https://www.laohu8.com/m/news/2386166643?lang=zh_cn&edition=full","pubTime":"2023-11-28 10:07","pubTimestamp":1701137240,"startTime":"0","endTime":"0","summary":"图源自视觉中国11月27日，四环生物（000518.SZ）开盘一字涨停晋级4连板，股价创2021年2月以来新高，报4.57元，最新总市值47.05亿元。24日，四环生物还曾发布关于股票交易异常波动的公告，称近期公司经营情况及内外部经营环境未发生重大变化。上周开始，抗流感概念在资本市场备受关注，多只个股收获涨停板，但目前来看，多地...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/Os_hs5u6PmEURTydvGx_V-aFOW1b3YgI1OZRmfPQXp7UcAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/Os_hs5u6PmEURTydvGx_V-aFOW1b3YgI1OZRmfPQXp7UcAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20231128A02CPF00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20231128A02CPF00","is_publish_highlight":false},{"id":"2386783181","title":"葛兰素史克(GSK.US)血癌药物Blenrep在研究中帮助患者延长寿命","url":"https://stock-news.laohu8.com/highlight/detail?id=2386783181","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2386783181?lang=zh_cn&edition=full","pubTime":"2023-11-27 19:35","pubTimestamp":1701084900,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克表示，其抗体药物Blenrep在一项后期研究中帮助患者延长了寿命，而血癌没有恶化。该药物去年在美国被撤销了许可。葛兰素史克在一份声明中表示，与另外两名年龄较大的患者一起服用该药的志愿者相比，接受标准治疗方案的对照组在初始治疗后复发的骨髓瘤表现更好。Blenrep是葛兰素史克在癌症治疗领域努力的一部分，但该公司去年遭遇挫折，在一项临床试验失败后，美国监管机构撤销了对Blenrep的批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1029793.html","is_publish_highlight":false},{"id":"2386929214","title":"1600亿疫苗龙头重磅宣布，进军减肥药！外资最新关注度曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2386929214","media":"数据宝","top":-1,"share":"https://www.laohu8.com/m/news/2386929214?lang=zh_cn&edition=full","pubTime":"2023-11-26 17:43","pubTimestamp":1700991780,"startTime":"0","endTime":"0","summary":"智飞生物是疫苗龙头，市值接近1600亿元，近期获得185家机构调研。2023年第三季度，公司实现营业收入148.26亿元，同比增长56.57%；实现归属于上市公司股东净利润22.70亿元，同比增长20.89%。本次协议的签署确定了重组带状疱疹疫苗未来三年的最低年度采购金额，合计超200亿元，保障了协议产品的基础供应。智飞生物是近一周外资机构关注度最高的个股，合计有38家海外机构调研。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA4MDU0MzQ4Mg==&mid=2653348756&idx=1&sn=bc9e70cbf4a2d0cee8cb039a0bcd9e10&chksm=8470e801b3076117e88691654d025a4abb10e947acd66da317228255f2f120ed7011c19e36df#rd","is_publish_highlight":false},{"id":"2385604444","title":"“左手默沙东、右手GSK”之后，1600亿疫苗巨头又要抢滩减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2385604444","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2385604444?lang=zh_cn&edition=full","pubTime":"2023-11-24 11:51","pubTimestamp":1700797865,"startTime":"0","endTime":"0","summary":"A股减肥药概念或再添新军","market":"sg","thumbnail":"https://img3.gelonghui.com/06664-55c6568d-a722-4b1c-8298-abcb950abe7e.jpg","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/06664-55c6568d-a722-4b1c-8298-abcb950abe7e.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/667485","is_publish_highlight":false},{"id":"2385676291","title":"葛兰素史克首批疟疾疫苗已运往非洲","url":"https://stock-news.laohu8.com/highlight/detail?id=2385676291","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2385676291?lang=zh_cn&edition=full","pubTime":"2023-11-24 04:03","pubTimestamp":1700769830,"startTime":"0","endTime":"0","summary":"葛兰素史克已将其首批、共331,200剂疟疾疫苗Mosquirix运往非洲。据悉，在该疫苗运往非洲之前，已经在加纳、肯尼亚和马拉维的试点项目中使用。资料显示，2021年，全球有61.9万人死于疟疾，其中96%发生在非洲。世界卫生组织的数据显示，五岁以下儿童尤其容易感染疟疾，在非洲地区与疟疾相关的死亡人数中，五岁以下儿童约占80%。Mosquirix是世界上第一款被批准用于对抗疟疾这种疾病的疫苗，该疫苗在去年正式获得世界卫生组织的批准。今年早些时候，世界卫生组织批准了第二种疟疾疫苗R21。\n\n\r\n            责任编辑：史文瑞","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2023/11/24040338548889.shtml","is_publish_highlight":false},{"id":"2385610942","title":"葛兰素史克(GSK.US)首批疟疾疫苗已运往非洲","url":"https://stock-news.laohu8.com/highlight/detail?id=2385610942","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2385610942?lang=zh_cn&edition=full","pubTime":"2023-11-23 14:40","pubTimestamp":1700721623,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克(GSK.US)已将其首批、共331,200剂疟疾疫苗Mosquirix运往非洲。据悉，在该疫苗运往非洲之前，已经在加纳、肯尼亚和马拉维的试点项目中使用。资料显示，2021年，全球有61.9万人死于疟疾，其中96%发生在非洲。世界卫生组织的数据显示，五岁以下儿童尤其容易感染疟疾，在非洲地区与疟疾相关的死亡人数中，五岁以下儿童约占80%。Mosquirix是世界上第一款被批准用于对抗疟疾这种疾病的疫苗，该疫苗在去年正式获得世界卫生组织的批准。今年早些时候，世界卫生组织批准了第二种疟疾疫苗R21。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1028164.html","is_publish_highlight":false},{"id":"2381128922","title":"（第六届进博会）葛兰素史克：中国的市场前景“毋庸置疑”","url":"https://stock-news.laohu8.com/highlight/detail?id=2381128922","media":"中国新闻网","top":-1,"share":"https://www.laohu8.com/m/news/2381128922?lang=zh_cn&edition=full","pubTime":"2023-11-06 14:35","pubTimestamp":1699252511,"startTime":"0","endTime":"0","summary":"第六届中国国际进口博览会已正式启幕，在华跨国企业如何随着“进博脚步”不断深入中国市场、发现未来前景？日前，葛兰素史克(下称“GSK”)副总裁、中国总经理齐欣与GSK副总裁、中国临床研发负责人籍纳新就此共同接受了中新社记者专访。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202311062895511658.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202311062895511658.html","is_publish_highlight":false},{"id":"2381542192","title":"葛兰素史克2023财年第三财季实现净利润18.53亿美元，同比增加107.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2381542192","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2381542192?lang=zh_cn&edition=full","pubTime":"2023-11-06 00:18","pubTimestamp":1699201101,"startTime":"0","endTime":"0","summary":"9月30日，葛兰素史克公布财报，公告显示公司2023财年第三财季净利润为18.53亿美元，同比增加107.74%；其中营业收入为103.10亿美元，同比增加12.02%，每股基本收益为0.91美元。从资产负债表来看，葛兰素史克总负债588.83亿美元，其中短期债务59.11亿美元，资产负债比为1.27，流动比率为0.95。机构评级：截至2023年9月30日，当前有19家机构对葛兰素史克目标价做出预测，其中目标均价为41.70美元，其中最低目标价为30.03美元，最高目标价为61.56美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231106001824824d993b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20231106001824824d993b&s=b","is_publish_highlight":false},{"id":"2380694772","title":"葛兰素史克盘中异动 早盘股价大跌5.01%报33.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2380694772","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2380694772?lang=zh_cn&edition=full","pubTime":"2023-11-01 21:39","pubTimestamp":1698845957,"startTime":"0","endTime":"0","summary":"北京时间2023年11月01日21时39分，葛兰素史克股票出现异动，股价大幅跳水5.01%。截至发稿，该股报33.91美元/股，成交量121.177万股，换手率0.06%，振幅1.95%。葛兰素史克股票所在的制药行业中，整体涨幅为0.06%。葛兰素史克公司简介：在制药行业，按总销售额计算，葛兰素史克是最大的公司之一。葛兰素史克利用合资企业在某些市场获得更大的规模。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202311012139188399043c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202311012139188399043c&s=b","is_publish_highlight":false},{"id":"2380383654","title":"RSV疫苗与带状疱疹疫苗需求强劲 葛兰素史克(GSK.US)再度上调全年业绩预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2380383654","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2380383654?lang=zh_cn&edition=full","pubTime":"2023-11-01 17:02","pubTimestamp":1698829333,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，由于市场对其突破性疫苗和带状疱疹疫苗 Shingrix的需求激增，英国医药巨头葛兰素史克今年第二次提高了其业绩展望数据。Arexvy是第一个获FDA批准的RSV疫苗，该疫苗目前获批的适用人群是60岁及以上的成年人。沃姆斯利表示，葛兰素史克目前正处于强劲而范围广泛的业绩增长轨道上。沃姆斯利此前面临着投资者要求其改进葛兰素史克产品线的压力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1018550.html","is_publish_highlight":false},{"id":"2379566315","title":"葛兰素史克(GSK.US)公布RUBY临床3期试验第1部分预定分析结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2379566315","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2379566315?lang=zh_cn&edition=full","pubTime":"2023-10-31 09:58","pubTimestamp":1698717492,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，10月30日，葛兰素史克公布RUBY临床3期试验第1部分预定分析的结果，该试验检视了PD-1抑制剂Jemperli与卡铂和紫杉醇联合用药，并接续Jemperli作为单药，与安慰剂加化疗后安慰剂相比，在原发性晚期或复发性子宫内膜癌成人患者中的疗效与安全性。子宫内膜癌是最常见的妇科癌症之一。在子宫内膜癌治疗方面，Jemperli已获美国FDA批准，作为在先前接受过含铂疗法后的dMMR晚期或复发性子宫内膜癌的单药治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1017709.html","is_publish_highlight":false},{"id":"2379562321","title":"港股异动 | 翰森制药(03692)再涨近8% 月内累涨逾40% 公司授权GSK开发权迎里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2379562321","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2379562321?lang=zh_cn&edition=full","pubTime":"2023-10-30 11:45","pubTimestamp":1698637538,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰森制药再涨近8%，月内累计涨幅超40%。截至发稿，涨7.95%，报15.2港元，成交额1.72亿港元。消息面上，翰森制药此前公告，将B7-H4ADC项目HS-20089大中华区以外的全球权益授予葛兰素史克，公司将收取8500万美元首付款、最多14.85亿美元里程碑付款以及商业化后销售净额的分级特许权使用费。该行指出，计及HS-20089，目前市场只有两项B7-H4ADCs处于临床阶段，相信与葛兰素史克合作，将会加快该药物发展进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1016103.html","is_publish_highlight":false},{"id":"2378794568","title":"葛兰素史克(GSK.US)艾滋病长效疗法在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2378794568","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2378794568?lang=zh_cn&edition=full","pubTime":"2023-10-27 20:03","pubTimestamp":1698408232,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，10月27日，葛兰素史克发布新闻稿称，其HIV药物专研合资公司ViiV Healthcare产品万凯锐与强生旗下强生创新制药产品瑞卡必已获得中国国家药品监督管理局批准联合使用，用于治疗已达到病毒学抑制的HIV-1感染者。GSK新闻稿指出，它同时也是NMPA批准的首个完整的HIV-1长效注射治疗方案。此次卡替拉韦注射液与利匹韦林注射液联合疗法的获批基于三项关键性研究数据：3期ATLAS和FLAIR研究，以及3b期ATLAS-2M研究，共计招募了来自16个国家的1200多名研究对象。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1014783.html","is_publish_highlight":false},{"id":"2378819419","title":"港股异动 | 翰森制药(03692)再涨超6% 公司授权GSK开发权迎里程碑 有望受惠ADC市场快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2378819419","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2378819419?lang=zh_cn&edition=full","pubTime":"2023-10-27 10:17","pubTimestamp":1698373051,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰森制药(03692)再涨超6%，截至发稿，涨5.87%，报13.34港元，成交额4662.79万港元。花旗发表报告指，翰森制药与葛兰素史克(GSK.US)订立许可协议，授予对方大中华以外地区开发及商业化HS-20089药物的权利，该产品是新型B7-H4靶向抗体药物偶联物(ADC)，根据公布的临床数据，客观缓解率(ORR)37.5%，前景良好，预计公司将会受惠ADC市场快速增长。该行指出，计及HS-20089，目前市场只有两项B7-H4 ADCs处于临床阶段，相信与葛兰素史克合作，将会加快该药物发展进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1013738.html","is_publish_highlight":false},{"id":"2378890786","title":"左手默沙东右手GSK，九价HPV疫苗带飞智飞生物，前三季度狂揽近400亿营收","url":"https://stock-news.laohu8.com/highlight/detail?id=2378890786","media":"时代周报","top":-1,"share":"https://www.laohu8.com/m/news/2378890786?lang=zh_cn&edition=full","pubTime":"2023-10-27 08:08","pubTimestamp":1698365307,"startTime":"0","endTime":"0","summary":"2023年半年报显示，智飞生物的自主产品营业收入为8.60亿元，同比减少48.44%。2018年，默沙东的九价HPV疫苗在国内获批上市，同一年，智飞生物与默沙东签订了经销与推广协议，获得九价HPV疫苗的独家代理权。在九价HPV疫苗的加持下，智飞生物的业绩也开始腾飞，逐步成为国内疫苗龙头。2023年上半年，九价HPV疫苗批签发量达到1467.82万支，同比增长57.85%，占智飞生物代理产品上半年批签发量的一半。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102708084282281438&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102708084282281438&s=b","is_publish_highlight":false},{"id":"2378090744","title":"葛兰素史克(GSK.US)旗下RSV疫苗于50至59岁年龄组III期试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2378090744","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2378090744?lang=zh_cn&edition=full","pubTime":"2023-10-25 16:50","pubTimestamp":1698223800,"startTime":"0","endTime":"0","summary":"智通财经获悉，葛兰素史克表示，该公司针对呼吸道合胞病毒的疫苗在一项后期试验中显示出积极的初步结果，该疫苗可保护50至59岁的成年人免受这种病毒的侵害——这种病毒每年导致数千人住院和死亡。RSV通常会引起类似感冒的症状，但也是幼儿和老年人肺炎的主要原因。这种疫苗已经在美国、欧洲、日本和其他国家被批准用于保护60岁及以上的成年人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-10-25/doc-imzsiftk2134074.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-10-25/doc-imzsiftk2134074.shtml","is_publish_highlight":false},{"id":"2377721271","title":"港股异动 | 翰森制药(03692)涨超7% 与GSK订立HS-20089许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2377721271","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2377721271?lang=zh_cn&edition=full","pubTime":"2023-10-24 09:52","pubTimestamp":1698112379,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰森制药涨超7%，截至发稿，涨6.34%，报12.08港元，成交额7500.69万港元。消息面上，10月20日，公司全资附属上海翰森生物医药科技与 GlaxoSmithKline Intellectual Property  Limited订立许可协议，据此GSK将获授予全球独占许可，以开发、生产及商业化HS-20089。据悉，HS-20089是一种新型B7-H4靶向抗体药物偶联，该产品正在中国进行用于治疗晚期实体瘤的一期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1010212.html","is_publish_highlight":false},{"id":"2377728297","title":"港股公告掘金 | 与GSK订立许可协议 ADC平台价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2377728297","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2377728297?lang=zh_cn&edition=full","pubTime":"2023-10-24 07:59","pubTimestamp":1698105591,"startTime":"0","endTime":"0","summary":"此次和GSK签订协议意味着HS-20089即将进入全球商业化收获阶段。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20190129/20190129153945_60530.png?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20190129/20190129153945_60530.png?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1010162.html","is_publish_highlight":false}],"profile":{"websiteUrl":"http://www.gsk.com","stockEarnings":[{"period":"1week","weight":-0.0172},{"period":"1month","weight":0.0251},{"period":"3month","weight":-0.0167},{"period":"6month","weight":0.0339},{"period":"1year","weight":-0.018},{"period":"ytd","weight":0.0228}],"compareEarnings":[{"period":"1week","weight":0.0024},{"period":"1month","weight":0.0525},{"period":"3month","weight":0.033},{"period":"6month","weight":0.0705},{"period":"1year","weight":0.1614},{"period":"ytd","weight":0.2034}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"GSK Plc于1999年12月6日在英国成立的公众服务有限公司，是一个世界领先的研究型制药和保健公司，由 Glaxo Wellcome plc和SmithKline Beecham plc合并而成。公司致力于开发较现有治疗方案明显改善的新产品，为病人和政府、保险公司或其他第三方提供帮助。","yearOnYearQuotes":[{"month":1,"riseRate":0.55814,"avgChangeRate":0.011068},{"month":2,"riseRate":0.44186,"avgChangeRate":-0.005044},{"month":3,"riseRate":0.604651,"avgChangeRate":0.020745},{"month":4,"riseRate":0.681818,"avgChangeRate":0.034223},{"month":5,"riseRate":0.386364,"avgChangeRate":-0.010964},{"month":6,"riseRate":0.613636,"avgChangeRate":0.014726},{"month":7,"riseRate":0.545455,"avgChangeRate":0.004705},{"month":8,"riseRate":0.568182,"avgChangeRate":0.001515},{"month":9,"riseRate":0.522727,"avgChangeRate":0.005813},{"month":10,"riseRate":0.522727,"avgChangeRate":0.013998},{"month":11,"riseRate":0.477273,"avgChangeRate":0.011509},{"month":12,"riseRate":0.590909,"avgChangeRate":0.013771}],"exchange":"NYSE","name":"葛兰素史克","nameEN":"GlaxoSmithKline PLC"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.19.1","shortVersion":"4.19.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葛兰素史克,GSK,葛兰素史克股票,葛兰素史克股票老虎,葛兰素史克股票老虎国际,葛兰素史克行情,葛兰素史克股票行情,葛兰素史克股价,葛兰素史克股市,葛兰素史克股票价格,葛兰素史克股票交易,葛兰素史克股票购买,葛兰素史克股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葛兰素史克(GSK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葛兰素史克(GSK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}